Effective targeting of the Epidermal Growth Factor Receptor (EGFR) for treating oral cancer: A promising approach

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1547-1552

  Ribeiro, Flávia Andressa Pidone ^a   Noguti, Juliana ^a   Oshima, Celina Tizuko Fujiyama ^a   Ribeiro, Daniel Araki ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Epidermal growth factor receptor; Oral cancer; Review

Indexed keywords

CELL SURFACE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; DNA POLYMORPHISM; DNA SYNTHESIS; DRUG TARGETING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; METASTASIS POTENTIAL; MOUTH CANCER; PATHOGENESIS; PHENOTYPE; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; DRUG ANTAGONISM; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUTH TUMOR; MUTATION; REVIEW;

EPIDERMAL GROWTH FACTOR RECEPTOR; ORAL CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; MOUTH NEOPLASMS; MUTATION; POLYMORPHISM, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84902239726     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Grandis J and Tweardy D: Elevated levels of transforming growth factor alpha and epidermal growth factor recetor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584, 1993.
2. Okamoto I: Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 277: 309-315, 2010.
3. Mitsudomi T and Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277: 301-308, 2010.
4. Jemal D, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
5. Parkin D, Bray F, Ferlay J and Pisani P: Global cancer statistics. Cancer J Clin 55: 74-108, 2005.
6. Xi S and Grandis J: Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res 82: 11-16, 2003.
7. Magrath I and Litvak J: Cancer in developing countries: opportunity and challenge. J Nat Cancer Inst 85: 862-874, 1993.
8. Berenson J, Yang I and Mickel R: Frequent amplification of the BCL-1 locus in head and neck squanous cell carcinomas. Oncogene 4: 1111-1116, 1989.
9. Fergunson K, Berger M, Mendrola J, Cho H, Leahy D and Lemmon M: EGF activates its receptor by removing interactions that autoinhibit cetodomain dimerization. Mol Cell 11: 507-517, 2003.
10. Yarden Y: The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities. Eur J Cancer 4: S3-S8, 2001.
11. Ullrich A, Coussens L, Hayflick J, Dull T, Gray A, Tam A, Lee J, Yarden Y, Libermann T and Schlessinge J: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309(5967): 418-425, 1984.
12. Lo H and Hung M: Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 94: 184-188, 2006.
13. Yarden Y, Shilo B: SnapShot: EGFR signaling pathway. Cell 131: 1018, 2007.
14. Campos ADA, Rodrigues M, Andrade CD, Goes AD, Nathanson M and Gomes D: Epidermal growth factor receptors destined for the nucleus are internalized via a clathrin-dependent pathway. Biochem Biophys Res Commun 412(2): 341-346, 2011.
15. Lo H: Nuclear Mode of the EGFR Signaling Network: Biology, Prognostic Value, and Therapeutic Implications. Discov Med July 10(50): 44-51, 2010.
16. Lo H, Xia W, Wei Y, Ali-Seyed M, Huang S and Hung M: Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 65(1): 338-348, 2005.
17. Kamio T, Shigematsu K, Sou H, Kawai K and Tsuchiyama H: Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 21(3): 277-282, 1990.
18. Marti U, Ruchti C, Kampf J, Thomas G, Williams E, Peter H, Gerber H and Burgi U: Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 11(2): 137-145, 2001.
19. Psyrri A, Yu Z, Weinberger P, Sasaki C, Haffty B, Camp R, Rimm D and Burtness B: Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11 (16): 5856-5862, 2005.
20. Ferguson K, Berger M and Mendrola J: EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507-517, 2003.
21. Olayioye M, Neve R, Lane H and Hynes N: The ErbB siganling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
22. Cho H and Leahy D: Structure of the extracellular region of HER3 reveals an inter-domain tether. Science 297: 1330-1333, 2002.
23. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW and Ward CW: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation poised to interact with other ErbB receptors. Mol Cell 11: 495-505, 2003.
24. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M and Yokoyama S: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787, 2002.
25. Schneider M and Wolf E: The epidermal growth factor receptor ligands at a glance. J Cell Physiol 218: 460-466, 2009.
26. III KC, Weber J, Unger M, Ledesma J, Yu N, Gassmann M and Lai C: Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 387(6632): 512-516, 1997.
27. Chang H, 2nd DRD, Gilbert W, Stern D and McMahan U: Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 387(6632): 509-512, 1997.
28. Harari D, Tzahar E, Romano J, Shelly M, Pierce J, Andrews G and Yarden Y: Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 18 (17): 2681-2689, 1999.
29. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW and Ward CW: Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110: 763-773, 2002.
30. Bouyain S, Longo P, Li S, Ferguson K and Leahy D: The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci USA 102: 15024-15029, 2005.
31. Dawson J, Berger M, Lin C, Schlessinger J, Lemmon M and Ferguson K: Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol 25: 7734-7742, 2005.
32. Garrett T, McKern N, Lou M, Elleman T, Adams T, Lovrecz G, Kofler M, Jorissen R, Nice E, Burgess A and Ward C: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11(2): 495-505, 2003.
33. Cho HS, Mason KX, Ramyar K, Stanley AM, Gabelli SB, Denney DW Jr. and Leahy DJ: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421(6924): 756-760, 2003.
34. Miettinen P, Berger J, Meneses J, Phung Y, Pedersen R, Werb Z and Derynck R: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376(6538): 337-341, 1995.
35. Siwak D, Carey M, Hennessy B, Nguyen C, Murray MM, Nolden L and Mills G: Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 568938, 2010.
36. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin B and Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287, 1996.
37. Hynes N and Lane H: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev 5: 341-354, 2005.
38. Brinkman B and Wong D: Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol 18(3): 228-233, 2006.
39. Weigum S, Floriano P, Christodoulides N and McDevitt J: Cellbased sensor for analysis of EGFR biomarker expression in oral cancer. Lab Chip 7: 995-1003, 2007.
40. Tandon AK, Clark GM, Chamness GC, Ullrich A and McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128, 1989.
41. Ulanovski D, Stern Y, Roizman P, Shpitzer T, Popovtzer A and Feinmesser R: Expression of EGFR and Cerb-B2 as prognostic factors in cancer of the tongue. Oral Oncology 40: 532-537, 2004.
42. Yamada T, Takagi M, Shioda S: Evaluation of epidermal growth factor receptor in squamous cell carcinoma of the oral cavity. Oral Surg Oral Med Oral Pathol 73: 67-70, 1992.
43. Rubin Grandis J1, Melhem MF, Barnes EL and Tweardy DJ: Quantitive immunohistochemical analysis of transformation growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma in head and neck. Cancer J Clin 78(6): 1284-1292, 1996.
44. Chung C, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy B, Netterville J, Burkey B, Sinard R, Cmelak A, Levy S, Yarbrough W, Slebos R and Hirsch F: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170-4176, 2006.
45. Temam S, Kawaguchi H, El-Naggar A, Jelinek J, Tang H, Liu D, Lang W, Issa J, Lee J and Mao L: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25: 2164-2170, 2007.
46. Modjtahedi H and Essapen S: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20: 851-855, 2009.
47. Chang K, Tsai S, Chen S, Tsou H, Yen C, Liu K, Fang H, Wu H, Chou S, Tang C, Liu S, Lu P, Yen C and Chang J: Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. J Bio Med Sci 20: 43, 2013.
48. Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong D, Barbieri V, Jank S, Doppler W, Rasse M and Norer B: High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis. Oral Oncology 43: 193-198, 2007.
49. Lo H, Hsu S, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih J and Hung M: Nuclear interaction of EGFR and STAT3 in the activation of iNOS/NO pathway. Cancer Cell 7: 575-589, 2005.
50. Lo H, Hsu S and Hung M: EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear trans-localization. Breast Cancer Res Treat 1-8, 2005.
51. Lin S, Makino K, Xia W, Matin A, Wen Y, Kwong K, Bourguignon L and Hung M: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-880, 2001.
52. Cao H, Lei Z, Bian L and Rao C: Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. Endocrinology 136: 3163-3317, 1995.
53. Gebhardt F, Burger H and Brandt B: Modulation of EGFR gene transcription by a polymorphic repetitive sequence-a link between genetics and epigenetics. Int J Biol Markers 15(1): 105-110, 2000.
54. Schwentner I, Witsch-Baumgartner M, Sprinzl GM, Krugmann J, Tzankov A, Jank S, Zwierzina H and Loeffler-Ragg J: Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. Head Neck 30(8): 1040-1044, 2008.
55. Bornstein P, McKay J, Liska DJ, Apone S and Devarayalu S: Interactions between the promoter and first intron are involved in transcriptional control of alpha 1 (I) collagen gene expression. Mol Cell Biol 8: 4851-4857, 1988.
56. Gebhardt F, Burger H and Brandt B: Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations - a link between genetics and epigenetics. Histol Histopathol 15: 929-936, 2000.
57. Gebhardt F, Zanker KS and Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274: 13176-13180, 1999.
58. Perea S, Oppenheimer D and Amador M: Genotypic bases of EGFR inhibitors pharmacological actions. Proc Am Soc Clin Oncol 23: 196 (Abstr 3005), 2004.
59. Tang PA, Tsao M-S and Moore MJ: A review of erlo-tinib and its clinical use. Expert Opin Pharmacother 7: 177-193, 2006.
60. Orcutt KP, Parsons AD, Sibenaller ZA, Scarbrough PM, Zhu Y, Sobhakumari A, Wilke WW, Kalen AL, Goswami P, Miller FJ Jr., Spitz DR and Simons AL: Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. Cancer Res 71: 3932-3940, 2011.
61. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR and Bigner DD: The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 4(2): 148-58, 1998.
62. Pedersen MW, Meltorn M, Damstrup L and Poulsen HS: The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12(6): 745-760, 2001.
63. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB and Wong AJ: Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273(1): 200-206, 1998.
64. Huang S, Bock J and Harari P: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940, 1999.
65. Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Chaudhry MA, Wahl R, Forastiere A and Gillison M: A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clin Cancer Res 18(6): 1735-1742, 2012.
66. Kwok TT and Sutherland RM: Differences in, EGF-related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer 64: 251-254, 1991.
67. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H Mendelsohn J and Hong WK: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7(5): 1204-1213, 2001.
68. Huang SH and O'Sullivan B: Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal 18(2):e233-240, 2013.
69. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J and Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511-529, 1983.
70. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH and Mendelsohn J: Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an antireceptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337-1341, 1983.
71. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G and Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by antiepidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002-1007, 1984.
72. Goldstein NI, Prewett M, Zuklys K, Rockwell P and Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311-1318, 1995.
73. Masui H, Moroyama T and Mendelsohn J: Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor mono-clonal antibodies with different isotypes. Cancer Res 46: 5592-5598, 1986.
74. Fan Z, Masui H, Altas I and Mendelsohn J: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53: 4322-4328, 1993.
75. Li X and Fan Z: The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 70: 5942-5952, 2010.
76. Ren JH, He WS, Nong L, Zhu QY, Hu K, Zhang RG, Huang LL, Zhu F and Wu G: Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm 25: 75-80, 2010.
77. Chen S, Rehman SK, Zhang W, Wen A, Yao L and Zhang J: Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 1806: 220-229, 2010.
78. Lomonaco SL, Finniss S, Xiang C, Decarvalho A, Umansky F, Kalkanis SN, Mikkelsen T and Brodie C: The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 125: 717-722, 2009.
79. Fung C, Lock R, Gao S, Salas E and Debnath J: Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 19: 797-806, 2008.
80. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T and Thompson CB: Growth factor regulation of autoph-agy and cell survival in the absence of apoptosis. Cell 120: 237-248, 2005.
81. Mazure NM, Pouysségur J: Hypoxia-induced autoph-agy: cell death or cell survival? Curr Opin Cell Biol 22: 177-180, 2010.
82. Ciardiello F and Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970, 2001.
83. Harari PM, Huang SM, Herbst RS and Quon H: Molecular Targeting of the Epidermal Growth Factor Receptor. In: Harrison LB, Session RB, Hong WK, editors. Head and Neck Cancer: A Multidisciplinary Approach. 2nd ed. Philadelphia: Lippincott, Williams and Wilkings, 2003.
84. Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, Allal BC, Courbon F, Chatelut E and Delord JP: Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 13: 7086-7092, 2007.
85. Soulieres D, Senzer NN, Vokes EE, Hidalg M, Agarwala SS and Siu LL: Multicenter phase II study of erlotinib and oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77-85, 24.